<DOC>
	<DOCNO>NCT01544582</DOCNO>
	<brief_summary>This observational prospective follow-up study assess utilization boceprevir management pre-specified health outcome interest ( HOIs ) condition routine clinical care participant chronic hepatitis C ( CHC ) genotype 1 . As observational prospective study , study intend change participant/physician relationship , influence physician 's drug prescription therapeutic management participant . No individual administration therapeutic prophylactic agent assign protocol , procedure require part protocol . Physician choice drug use treat participant base clinical judgment alone .</brief_summary>
	<brief_title>Drug Utilization Boceprevir Clinical Management Health Outcomes Interest Chronic Hepatitis C Participants ( P08518 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Documented chronic hepatitis C ( CHC ) genotype1 infection Untreated fail previous therapy Initiated new treatment regimen study implementation date site Agrees participate study give write informed consent Taking part clinical trial study participant receive care outside normal clinical practice Hepatitis C Virus ( HCV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Pegylated Interferon</keyword>
	<keyword>boceprevir</keyword>
	<keyword>telaprevir</keyword>
</DOC>